{"filing":{"accession_number":"0001703057-26-000035","cik":"0001703057","ticker":"ABCL","company_name":"AbCellera Biologics Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"abcl-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000035/abcl-20260617.htm"},"events":[{"id":11490,"run_id":10087,"accession_number":"0001703057-26-000035","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"AbCellera announced a preclinical research collaboration and option/license agreement for T-cell engaging multispecific antibodies targeting GI cancers and solid tumors. While this represents a material strategic partnership leveraging the company's core antibody discovery platform, it does not fit cleanly into more specific event categories (not an M\u0026A transaction, not an earnings release, not an executive change). The disclosure would affect a reasonable investor's assessment of the company's pipeline and strategic direction, warranting material classification under \"other_material.\"","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8088,"accession_number":"0001703057-26-000035","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"AbCellera announced a preclinical research collaboration and option/license agreement for T-cell engaging multispecific antibodies targeting GI cancers and solid tumors. While this represents a material strategic partnership leveraging the company's core antibody discovery platform, it does not fit cleanly into more specific event categories (not an M\u0026A transaction, not an earnings release, not an executive change). The disclosure would affect a reasonable investor's assessment of the company's pipeline and strategic direction, warranting material classification under \"other_material.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T16:39:06.998680+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8088,"accession_number":"0001703057-26-000035","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"AbCellera announced a preclinical research collaboration and option/license agreement for T-cell engaging multispecific antibodies targeting GI cancers and solid tumors. While this represents a material strategic partnership leveraging the company's core antibody discovery platform, it does not fit cleanly into more specific event categories (not an M\u0026A transaction, not an earnings release, not an executive change). The disclosure would affect a reasonable investor's assessment of the company's pipeline and strategic direction, warranting material classification under \"other_material.\"","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T16:39:06.998680+00:00","company_name":"AbCellera Biologics Inc.","ticker":"ABCL","filing_date":"2026-06-17"}]}